2026-01-07, 6:52:17 a.m.
Toronto, Ontario — January 7, 2026 — Leads & Copy — Ventripoint Diagnostics Ltd. (TSXV:VPT) announced it would double its previously announced non-brokered private placement from $500,000 to $1,000,000 in response to investor interest, subject to TSX Venture Exchange approval.
Each unit will include one common share of the corporation and one common share purchase warrant.
Each whole warrant will allow the holder to purchase one common share at $0.13 for 24 months from the offering’s closing. The corporation can accelerate the warrant expiry period with 30 days’ notice if the common shares trade at $0.26 or above on the TSXV for 10 consecutive days, including days with no trades.
The corporation may pay cash finder’s fees and issue common share purchase warrants of up to 8% of the offering’s gross proceeds. Each finder’s warrant can be exercised into one common share at CDN$0.13 per share for 24 months from the offering’s closing.
The corporation will use the proceeds to support commercialization, manufacturing scale-up, regulatory submissions, and operational needs.
All securities issued will be subject to a four-month hold period plus one day from the offering’s closing date. The offering is subject to exchange approval.
Ventripoint is an industry leader in applying AI to echocardiography. Its VMS+ products use proprietary knowledge-based reconstruction technology, providing cardiac measurements equivalent to MRI. The VMS+ is versatile and works with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.
For further information, please contact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201
Source: Ventripoint Diagnostics Ltd.
